Consort Partners’ Post

Personalis, Inc. and Myriad Genetics have announced a cross-licensing agreement to enhance their operations and elevate MRD cancer testing results. For more details on this partnership and their previous collaborations, check out Precision Medicine Online's story! #MRD #Partnership #Oncology #MRDTest #CancerTest #PrecisionOncology

Big moves in the fight against prostate cancer! Merck has just landed exclusive global rights to opevesostat, a potential game-changer for metastatic castration-resistant prostate cancer. Fresh off their collaboration with Orion Corporation, Merck is now steering the wheel solo in the Phase 3 trials 📊✅ Orion's handover is strategic, allowing them to channel their energies into other projects while staying on board the opevesostat journey through milestones and royalties. It's about smarter resource allocation and trust in Merck's ability to push the boundaries further 🚀 With Orion's eyes on a large sum of milestones reaching up to $625 million, not to mention the potential $975 million in sales milestones, transparent partnerships like these show us the value of joining forces in the Life Sciences 🤝 #Merck #OrionCorporation #LiisaHurme #Oncology #ProstateCancer #LifeScience #ClinicalResearch #ClinicalTrials #Biotechnology #Pharmaceuticals #ElixirAssociates

Exciting times ahead for Bivictrix Therapeutics Ltd! 🚀 We've reached a significant milestone as we transition from our AIM listing to becoming a private company. This move allows us to accelerate the development of our cutting-edge bispecific ADCs and stay competitive in this rapidly evolving space. What’s been happening recently? 🌟 BVX002 progress: Our lead solid tumour asset has shown remarkable preclinical results in an ovarian cancer model, with data exceeding expectations. The positive results strengthen our belief in the potential of our platform for solid tumours. 🌟 More models: We're expanding our research with additional tumour models and will be sharing more efficacy and safety data soon. Stay tuned as we move closer to selecting a clinical candidate for BVX002! 🌟 Pipeline growth: We're building a proprietary library of novel antigen combinations focused on solid tumours, with more candidates on the horizon. Our lead asset, BVX001, also continues to make strong progress in terms of safety and efficacy for the treatment of acute myeloid leukaemia, AML. This transition to private status puts us in a stronger position to push forward with our groundbreaking research and bring new treatments to patients faster. Watch this space – there's more to come! 💥 #biotech #ADC #oncology #solidtumors #DrugDevelopment

This year it is my privilege to chair the annual DDR Inhibitors Summit https://lnkd.in/eVg3Xh8q, taking place next week 30 Jan-1 Feb in Boston. The international meeting brings together people who, like me, are passionate about the opportunity to develop new, urgently needed cancer medicines through targeted interference with DNA damage response (DDR) pathways.   As you know, developing small molecule therapeutics that modulate DNA damage responses is the focus of Breakpoint Therapeutics GmbH. Therefore, my colleague Jon Hollick and I are excited to go to the DDR Inhibitors Summit, meet with other experts from industry and academic research institutions and catch up with peers, collaborators and potential pharma partners.   We look forward to many interesting presentations and discussions, including the panel with my esteemed colleagues Mark O'Connor from AstraZeneca and Charles Sinclair from Flagship Pioneering on “What Makes the Perfect Next-Generation DDR Inhibitor Target?” that I will moderate. And Jon will present a poster describing some highlights from our own PolQ program which you shouldn’t miss.   I believe registration is still possible. So if you are passionate about DDR inhibitors, join us in Boston! #DDR #drugdiscovery #precisionmedicine #oncology

I am pleased to be on participating in the 7th DDR Inhibitors Summit this week, renewing connections and I am looking forward to hearing from peers about their progress. In 2023 I gave an invited talk unveiling Breakpoint Therapeutics GmbH and the work we have been doing to discover modulators of DNA damage response and repair for the treatment of cancer. This year I will be presenting data from our potential best in class polymerase theta inhibitor program. See you there! #ddr24 #ddrsummit #drugdiscovery #drugdevelopment #oncology

Unlock the potential of your oncology drug development with our OrganoidXplore™ screening service. Choose from a variety of panels including the Full, KRAS, Lung, CRC, and Flexible Panels to explore drug efficacy in over 50 detailed PDO and PDXO models. Benefit from: ✅Precision targeting with models covering key mutations like KRAS, BRAF, BRCA 1/2, and EGFR. ✅Comprehensive analysis using matched normal/disease pairs. ✅Fast, reliable results in 6-weeks with our semi-automated workflow and rigorous quality assurance. Register now to transform your research! ➡️https://bit.ly/3uVHMbB #Organoids #Oncology #Bioscience

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/g8XPQSsa #biotech #france #texas #oncology #artificialIntelligence

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update. We currently have two ongoing clinical trials addressing patients with unmet medical needs. ACESOT-1051, our next-generation WEE1 inhibitor targeting solid tumors with specific genetic markers. Early results show no adverse effects in the first cohort. Concurrently, we are progressing with the ABOYA-119 trial for our macrocyclic ATR inhibitor, ATRN-119, furthering our dedication to precision oncology. Aprea Therapeutics has $28.7 million in cash and cash equivalents as of June 30, 2024, with a cash runway extended into Q4 2025. Learn more: https://bit.ly/3WTZgip #InvestorRelations #IR #CancerResearch

In #ClinicalTrials investigating Antibody Drug Conjugates (#ADC\), worldwide regulators are asking sponsors to monitor for ILD toxicity. Understand the implications and how to meet #regulatory expectations in this webinar with Calyx's Rohit Sood MD., PhD., CFP https://lnkd.in/gV55MEPF #MedicalImaging #Oncology #ChooseCalyx

Big patent news for Vidac Pharma! The US patent office have issued a notice of allowance for the group of molecules that are the active compound in Vidac Pharma’s cancer drug candidates. “This U.S. patent goes to the heart of Vidac’s efforts to develop an entirely new class of cancer drugs for patients,” said Vidac Chief Executive Officer Prof. max herzberg. The patent will protect Vidac’s two drug candidates – VDA-1102 and VDA-1275 – which the company is developing to use in a wide range of tumors. Vidac’s family of molecules reverse the abnormal metabolism of cancer cells by dislodging the wrongly attached Hexokinase-2 enzyme from the mitochondrial VDAC pores. This stops rapid cell proliferation, restores immune-sensitivity and programmed cell death. Read our press release, more about the science behind our therapies, and the clinical results on our website: www.vidacpharma.com #biotech #oncology #drugdevelopment #bioscience #cancer